Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
对于年龄在 60 至 75 岁之间、预后良好且携带 NPM1 突变的急性髓系白血病 (AML) 患者，强化化疗与维奈托克/去甲基化药物的比较
期刊:
影响因子:
doi:10.1016/j.bneo.2025.100133
Zale, Andrew D; Sandeep Kaduluri, Venkata Preetam; Webster, Jonathan A; Levis, Mark J; Gojo, Ivana; DeZern, Amy E; Ghiaur, Gabriel; Gondek, Lukasz P; Dalton, William Brian; Karantanos, Theodoros; Jain, Tania; Prince, Gabrielle T; Jones, Richard J; Smith, B Douglas; Ambinder, Alexander J
